This year on EHA, we shared exciting new data on Imbruvica^® (ibrutinib) in RESONATE-2

Name: Imbruvica-News-Video
Uploaded: 2021-07-26T11:25:57.226Z
Description: Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.[^3] [^3]: Ghia P, et al. Up to 7 years of follow-up in the RESONATE-2 study of first-line ibrutinib for patients with chronic lymphocytic leukemia. Poster presented at: 26th congress of EHA; 9-12 June 2021; virtual meeting.

‌
‌

Categories / tags

SmPC

SmPC Imbruvica FR SmPC Imbruvica NL

CP-240988 - June 2021